Form 8-K - Current report:
SEC Accession No. 0001437749-25-026286
Filing Date
2025-08-12
Accepted
2025-08-12 17:27:58
Documents
13
Period of Report
2025-08-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dmtp20250812_8k.htm   iXBRL 8-K 42847
  Complete submission text file 0001437749-25-026286.txt   174056

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dmac-20250812.xsd EX-101.SCH 3579
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dmac-20250812_def.xml EX-101.DEF 11412
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dmac-20250812_lab.xml EX-101.LAB 15290
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dmac-20250812_pre.xml EX-101.PRE 11572
16 EXTRACTED XBRL INSTANCE DOCUMENT dmtp20250812_8k_htm.xml XML 2842
Mailing Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305
Business Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454
DiaMedica Therapeutics Inc. (Filer) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36291 | Film No.: 251208114
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)